Editor, vendor desk
Mara leads the vendor-audit desk at vialaudit. Before this she spent a decade covering pharmaceutical-supply transparency for trade publications, and a stint as an analyst at a generics-compounding firm — which is where she learned how COA practices vary in the wild and why most vendor reviews online aren't worth the bytes they're written in. Mara handles the vendor relationships, the audit-cycle calendar, the methodology page, and the corrections feed. She does not accept retainers, sponsored content, or paid feature placements. Vendors do not get to review their audits before publication. That's the job. She writes under a pen name. The grey-market context makes real-name bylines impractical for the writers and risky for the labs. The tradeoff is real and we'd rather work pseudonymously than not at all.
Vendor audits, vendor postmortems, regulatory enforcement (503A, FDA, EMA), comparison pieces, and the audit-cycle calendar.
The compounded semaglutide market that emerged during the 2022–2024 brand-product shortage is largely closed in 2026. Here's what the FDA shortage status, 503A PCAC restrictions, and telehealth provider pivots actually mean for buyers.
The 2024 and 2026 Pharmacy Compounding Advisory Committee votes did not close any peptide vendor. They closed the legal compounded telehealth channel — and that closure is what pushed demand toward the research-peptide market in the first place.
A timeline of FDA actions affecting the US research-peptide market from late 2024 through April 2026 — Warning Letters, criminal cases, and the 503A PCAC vote that reshaped what compounding pharmacies could legally produce.
Eight failure modes, ranked by how often they appear in public Janoshik data and how hard they are for a buyer to catch before ordering.
Amino Asylum, Peptide Sciences, and Paradigm Peptides each ceased operations under different circumstances. The signals that preceded each shutdown were public, dated, and ignored.
Two molecules from the same lab, different mechanisms, different regulatory states. The 2026 update folds in TRIUMPH Phase 3 data, the 503A compounding picture, and what that combination means for buyers and the literature.
Vendor landscape, COA verification, and what to know before ordering. Updated monthly.
Tips, corrections, or comments on vendor desk coverage: vendors@vialaudit.com
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.